Tirzepatide in Idiopathic Intracranial Hypertension Trial

Exclusion Criteria

• •1. Previous bariatric surgery
• •2. Prior intervention for high ICP including optic nerve sheath fenestration (ONSF), venous stenting and/or shunting
• •3. Taking another GLP-1 agonist, another drug that can interfere with the GLP-1 agonist, or any other anti-obesity medication
• •4. History of pancreatitis, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), history of gallbladder disease, ulcerative colitis, Crohn's disease, or history of hypersensitivity reaction in response to the drug
• •5. Pregnancy or planning a pregnancy in the next 12 months or currently breastfeeding
• •6. Other disorders causing visual loss and/or anomalous optic nerve
• •7. Taking another medication to lower ICP in IIH (if previously taking another medication for ICP must be off this medication for at least 30 days prior to enrollment)
• •8. No change in headache medications in the past 60 days
• •9. Venous sinus thrombosis on magnetic resonance venography (MRV)
• •10. Papilledema Frisen Grade III, IV or fulminant IIH
• •11. Mean perimetric deviation ≤ -7 dB
• •12. CSF contents outside of normal limits
• •13. Uncontrolled hypertension (≥140mmHg/90 mmHg)
• •14. Anemia (hemoglobin \[Hgb\] ≤ 8.0g/dL)
• •15. Diagnosed sleep apnea with continuous positive airway pressure (CPAP) use
• •16. Exposure to a drug, substance, or disorder that has been associated with elevation of intracranial pressure within 2 months of diagnosis such as lithium, vitamin A, various cyclines
• •17. eGFR \< 30 ml/min/1.73m2
• •18. Type II diabetes